Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, 77030, USA.
Cancer Causes Control. 2022 Mar;33(3):483-488. doi: 10.1007/s10552-021-01534-x. Epub 2022 Jan 11.
Congenital malformations are strong risk factors for childhood cancer. Our objective was to determine whether cancer survival differs by birth defect status among Oklahoma children.
We used accelerated failure time models to estimate survival time ratios (SRs) and 95% confidence intervals (CIs), adjusted for maternal race/ethnicity and census tract-level poverty, among children diagnosed with cancer and born in Oklahoma from 1997 to 2012 (n = 971), by linking records from birth certificates, birth defects, and cancer registries.
We observed decreased, though imprecise, survival time among survivors with any birth defect (SR: 0.82, 95% CI: 0.29, 2.31) or chromosomal defects (n = 24) (SR: 0.43, 95% CI: 0.06, 3.30) compared to those without birth defects. We observed no difference in survival time among children with non-chromosomal defects (SR: 0.98, 95% CI: 0.31, 3.12) compared to children with no birth defects.
Our study did not identify significant differences in cancer survival for children with and without birth defects. Future studies should consider pooling data from multiple states to allow in-depth study of specific birth defects and cancer types and confirm whether survival differs by type and number of birth defects.
先天性畸形是儿童癌症的强烈危险因素。我们的目的是确定俄克拉荷马州儿童的癌症存活率是否因出生缺陷状况而异。
我们使用加速失效时间模型,通过链接出生证明、出生缺陷和癌症登记处的记录,在从 1997 年到 2012 年期间(n=971),对在俄克拉荷马州诊断出患有癌症且出生的儿童,根据母亲的种族/民族和普查区贫困水平,调整生存时间比(SR)和 95%置信区间(CI),以评估患有癌症和存在出生缺陷的儿童的生存时间。
我们观察到,与无出生缺陷的幸存者相比,任何出生缺陷(SR:0.82,95%CI:0.29,2.31)或染色体缺陷(n=24)(SR:0.43,95%CI:0.06,3.30)的幸存者的生存时间缩短,但结果不精确。与无出生缺陷的儿童相比,我们观察到非染色体缺陷儿童(SR:0.98,95%CI:0.31,3.12)的生存时间无差异。
我们的研究未发现有出生缺陷和无出生缺陷的儿童的癌症存活率存在显著差异。未来的研究应考虑从多个州汇集数据,以便深入研究特定的出生缺陷和癌症类型,并确认生存时间是否因缺陷类型和数量而异。